| CAS No 205526-63-2 |
2-Hexyl-2,3,4,5,5-pentamethyl-3-imidazolinium-1-oxyl methyl sulfate null |
Inquiry |
| CAS No 204587-90-6 |
tert-Butyl (3S)-3-amino-4-hexenoate, 97% null |
Inquiry |
| CAS No 2033-81-0 |
1-(4-Bromobutoxy)-4-chlorobenzene null |
Inquiry |
| CAS No 203785-59-5 |
Chloromethyl-4-chlorophenoxy dimethylsilane, 98% null |
Inquiry |
| CAS No 2033-80-9 |
1-(4-Bromobutoxy)-4-fluorobenzeneHazard Risk Safety null |
Inquiry |
| CAS No 197234-17-6 |
Ethyl delta-bromo-beta,beta-dimethyl levulinate, 96% null |
Inquiry |
| CAS No 199926-39-1 |
Chelidamic acid monohydrate, 98% null |
Inquiry |
| CAS No 196707-32-1 |
(R)-N-BOC-4-Fluorophenylglycine, 95% null |
Inquiry |
| CAS No 190774-51-7 |
4-Fluoro-2-nitrophenyl isocyanate, 96% null |
Inquiry |
| CAS No 19230496 |
4'-Iodoacetanilide, 97%Hazard Risk Safety null |
Inquiry |
| CAS No 19047-85-9 |
Di-n-octadecyl phosphite null |
Inquiry |
| CAS No 189939-11-5 |
Cyclotriphosphazene-PMMH-6 Dendrimer, Generation 1.0 null |
Inquiry |
| CAS No 189939-12-6 |
Cyclotriphosphazene-PMMH-12 Dendrimer, Generation 1.5 null |
Inquiry |
| CAS No 18981-98-1 |
n-Heptyl sulfate, sodium salt, 99%Hazard Risk Safety null |
Inquiry |
| CAS No 188777-48-2 |
(S)-(+)-N(alpha)-Benzyl-N(beta)-BOC-(L)-hydrazinoserine, 98% null |
Inquiry |
| CAS No 1898-13-1 |
Cembrene, 99% null |
Inquiry |
| CAS No 188241-51-2 |
Hexakis(diethoxyphosphoryl)calix[6]arene, 97% null |
Inquiry |
| CAS No 18800-26-5 |
1-(2-Bromoethoxy)-2-chlorobenzene null |
Inquiry |
| CAS No 18800-28-7 |
1-(2-Bromoethoxy)-2-bromobenzene, 95% null |
Inquiry |
| CAS No 18780-67-1 |
4-Ethoxycarbonyloxy-3,5-dimethoxybenzoic acid, 96% null |
Inquiry |
| CAS No 184095-99-6 |
L(+)-2-Amino-6-(O,O'-diethylphosphono)hexanoic acid, 98% null |
Inquiry |
| CAS No 18751-99-0 |
alpha-Apo-oxytetracycline null |
Inquiry |
| CAS No 18383-58-9 |
trans-Chrysanthemyl alcohol, 98% null |
Inquiry |
| CAS No 180322-79-6 |
(1S,2S)-N-BOC-1-Amino-2-phenylcyclopropanecarboxylic acid null |
Inquiry |
| CAS No 18085-02-4 |
3,4-Diacetoxy-1-butene, 97% null |
Inquiry |
